What do Botox, rat poison, weight-loss drugs and a fictional murder investigation have in common? At the University of Nevada ...

Scientists at The Wistar Institute have shown that a single injection of a small, circular piece of genetic instruction can ...

Government College University Faisalabad (GCUF) has opened admissions for the Fall 2026-2027 session for undergraduate, ...

Achieved 100% ORR and 83.3% CR rate at dose level 2 following a single infusion in patients with relapsed/refractory B-NHL in an ongoing Phase 1 study No dose-limiting toxicities, serious adverse ...

Above the scientific discussions and deal talks at ASCO 2026, the dark cloud of geopolitics hovered over the Chicago convention center. (Angus Liu/Fierce Pharma) In 2017, a little-known company called ...

This buy brings the Denali Therapeutics stake to 2.12% of ADAR1’s reported equity assets after the first quarter. Top holdings after the filing: NASDAQ: ABVX: $155.22 million (9.4% of AUM) NASDAQ: ...

The most advanced clinical trial for an in vivo gene editor, lonvoguran ziclumeran (lonvo-z) reported positive phase 3 results in hereditary angioedema. Intellia Therapeutics announced that its ...

Critical Hartford and Connecticut business news updated daily. Immediate access to all subscriber-only content on our website. Bi-weekly print or digital editions of our award-winning publication.

Several pharmaceutical stocks have surged in wake of a hantavirus outbreak as investors gauge whether they could benefit from developing vaccines. Moderna, Inovio, and Novavax surged in early trading ...

The First Trust NYSE Arca Biotechnology ETF (FBT Quick Quote FBT - Free Report) was launched on 06/19/2006, and is a smart beta exchange traded fund designed to offer broad exposure to the Health Care ...

- Global strategic collaboration with Astellas to advance PSMA-targeted, PRO-XTEN® dual-masked T-cell engager (TCE) VIR-5500 closed and first patient dosed in Phase 1 dose-expansion cohorts in ...

The biotech IPO window looks like it’s reopening. This past week closed with three biotech companies joining the public markets, a flurry of activity that helped make April the biggest month for ...